Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. [electronic resource]
Producer: 19991122Description: 2309-18 p. digitalISSN:- 0004-3591
- Adolescent
- Adrenal Cortex Hormones -- adverse effects
- Adult
- Aged
- Aged, 80 and over
- Analysis of Variance
- Biomarkers
- Bone Resorption -- chemically induced
- Calcium Channel Blockers -- adverse effects
- Demography
- Double-Blind Method
- Etidronic Acid -- adverse effects
- Female
- Humans
- Male
- Middle Aged
- Risedronic Acid
No physical items for this record
Publication Type: Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
There are no comments on this title.
Log in to your account to post a comment.